Genentech's Immunology/Infectious Disease Deal Maker On Following The Science

 
• By Jo Shorthouse

Genentech’s infectious diseases and immunology dealmaker speaks to Scrip about the significance of following the science when it comes to partnering.

Miniature people
Genentech had been closely monitoring the microbiome space for “at least four years” before a deal was struck • Source: Shutterstock

More from Deals

More from Business